9th Oct 2014 09:20
LONDON (Alliance News) - Vernalis PLC Thursday said it has licensed worldwide rights in vipadenant (V2006) to Boston-based start-up RedoxTherapies Inc for use in immuno-oncology.
According to Vernalis, vipadenant has the potential to disrupt an immunosuppressive mechanism of tumour protection, improving its ability to produce the results for immunotherapies of certain cancers when used in combination.
Vernalis did not disclose detailed financial terms of the licence agreement with Redox. However, Vernalis said it can earn "milestones and royalties" on successful clinical, regulatory and commercial advancement.
"We look forward to having Redox as a partner and to the progress of vipadenant into clinical studies in this exciting new setting for the potential benefit of cancer patients worldwide," Vernalis Chief Executive Ian Garland said in a statement.
Vernalis shares were Thursday quoted up 1.1% at 48.00 pence.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC